30.11.2021 20:15

United States $200+ Million Pharmaceutical Isolators Markets to 2028 - Growth is Primarily Driven by Continuous Progress in the Field of Medicines and Bioscience


DUBLIN, Nov. 30, 2021 /PRNewswire/ -- The "U.S. Pharmaceutical Isolators Market Size, Share & Trends Analysis Report By Type (Open Isolator, Close Isolator), By Pressure (Positive Pressure, Negative Pressure), And Segment Forecasts, 2020 - 2028" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The U.S. pharmaceutical isolators market size is expected to reach USD 205.2 million by 2028, registering a CAGR of 5.8% from 2020 to 2028

The rapid growth of the pharmaceutical industry in the U.S. and advancements in technologies used in the industry are anticipated to have a positive impact on market growth.

The growth of the industry in the U.S. is primarily driven by continuous progress in the field of medicines and bioscience. The rising demand for aseptically processed parenteral medicines, along with increased investments in the industry, is anticipated to drive the market in the U.S.

Pharmaceutical isolators are seeing fast-paced technological advancements in aseptic processing in terms of incorporation of robotics and automation solutions and industry 4.0. By integrating robotics within gloveless pharmaceutical isolators, the risk of microbe contamination, as well as particle contamination caused by human intervention is reduced.

The industry is moving toward energy efficiency and sustainability. Pharmaceutical isolators offer higher energy efficiency as compared to the Restricted Access Barrier System (RABS). Energy saving in pharmaceutical isolators can be up to 65% as compared to 30% offered by RABS which is likely to positively improve their demand.

U.S. Pharmaceutical Isolators Market Report Highlights

  • The closed isolators segment is expected to witness a CAGR of 5.5% from 2020 to 2028 owing to the ability to operate without personnel access to the critical zone, making them suitable for application in the preparation of toxic materials
  • The positive pressure segment accounted for 53.9% of the overall revenue share in 2020, owing to its demand in sterile processes when the process is of particular significance and keeping any contaminants out of the isolator is a priority
  • Companies are collaborating with educational institutions along with their in-house R&D facilities for developing processes and technologies that offer a sustainable advantage in the future
  • In February 2021, Comecer S.p.A partnered with Illuminate Manufacturing Intelligence, to integrate Illuminate, a pharmaceutical production solution based on industry 4.0, to get real-time updates of their manufacturing equipment

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. U.S. Pharmaceutical Isolators Market Variables, Trends, & Scope

Chapter 4. U.S. Pharmaceutical Isolators Market: Type Estimates & Trend Analysis

Chapter 5. U.S. Pharmaceutical Isolators Market: Pressure Estimates & Trend Analysis

Chapter 6. U.S. Pharmaceutical Isolators Market: Competitive Analysis

Chapter 7. Company Profiles

  • Comecer S.P.A.
  • Laf Technologies
  • Iso Tech Design
  • Nuaire
  • Getinge Ab
  • Skan Ag
  • M. Braun Inertgas-Systeme Gmbh
  • Azbil Telstar, S.L.U.
  • Syntegon Technologies Gmbh
  • IMA Group

For more information about this report visit https://www.researchandmarkets.com/r/4r17nf

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:https://www.prnewswire.com/news-releases/united-states-200-million-pharmaceutical-isolators-markets-to-2028---growth-is-primarily-driven-by-continuous-progress-in-the-field-of-medicines-and-bioscience-301433900.html

SOURCE Research and Markets

Börse Stuttgart Anlegerclub

Heute im Fokus

US-Börsen letztlich uneins -- DAX geht schwächer ins Wochenende -- WACKER CHEMIE übertrifft Erwartungen 2021 -- SAP zieht Tempo im Cloudgeschäft an -- JPMorgan, Citigroup, Wells Fargo, DWS im Fokus

AT&T und Dish geben Milliarden für Frequenzen für 5G-Dienste aus. Corona-Impfstoff von Novavax soll ab 21. Februar verfügbar sein. Drägerwerk mit Umsatzeinbußen. Wechsel im AUDI-Aufsichtsrat. Nagarro will Umsatz 2022 um fast ein Drittel steigern. Siemens-Kunden müssen wohl auf Steuerungs-Chips warten. EZB: Lagarde rechnet mit Inflationsrückgang 2022. Streit um Zukunft von Generali-Chef eskaliert im Verwaltungsrat.


Wo steht der DAX zum Jahresende 2022?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln